For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20231123:nRSW5087Ua&default-theme=true
RNS Number : 5087U AstraZeneca PLC 23 November 2023
23 November 15:00 GMT
Transaction by Person Discharging Managerial Responsibilities
AstraZeneca PLC (the Company) announces that, on 22 November, it was notified
of the following transactions in the Company's ordinary shares of $0.25 each
(Ordinary Shares) by Michel Demaré, Non-Executive Chair of the Board.
PDMR Position Nature of the transaction Date Quantity Price
Michel Demaré Non-Executive Chair of the Board Purchase of Ordinary Shares 21/11/2023 1,000 GB£101.05
Michel Demaré Non-Executive Chair of the Board Purchase of Ordinary Shares 22/11/2023 1,000 GB£101.70
Further details are set out in the attached notifications, made in accordance
with the requirements of the EU Market Abuse Regulation (since it forms part
of UK law pursuant to the European Union (Withdrawal) Act 2018).
1 Details of the person discharging managerial responsibilities / person closely
associated
a) Name Michel Demaré
2 Reason for the notification
a) Position/status Non-Executive Chair of the Board
b) Initial notification /Amendment Initial notification
3 Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name AstraZeneca PLC
b) LEI PY6ZZQWO2IZFZC3IOL08
4 Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument, type of instrument Ordinary Shares of US$0.25 each in AstraZeneca PLC
Identification code
GB0009895292
b) Nature of the transaction Purchase of AstraZeneca PLC Ordinary Shares of US$0.25
c) Price(s) and volume(s)
Price(s) Volume(s)
£101.05224 1,000
d) Aggregated information Not applicable - single transaction
- Aggregated volume
- Price
e) Date of the transaction 21 November 2023
f) Place of the transaction LON
d)
Aggregated information
- Aggregated volume
- Price
Not applicable - single transaction
e)
Date of the transaction
21 November 2023
f)
Place of the transaction
LON
1 Details of the person discharging managerial responsibilities / person closely
associated
a) Name Michel Demaré
2 Reason for the notification
a) Position/status Non-Executive Chair of the Board
b) Initial notification /Amendment Initial notification
3 Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name AstraZeneca PLC
b) LEI PY6ZZQWO2IZFZC3IOL08
4 Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument, type of instrument Ordinary Shares of US$0.25 each in AstraZeneca PLC
Identification code
GB0009895292
b) Nature of the transaction Purchase of AstraZeneca PLC Ordinary Shares of US$0.25
c) Price(s) and volume(s)
Price(s) Volume(s)
£101.70 1,000
d) Aggregated information Not applicable - single transaction
- Aggregated volume
- Price
e) Date of the transaction 22 November 2023
f) Place of the transaction LON
d)
Aggregated information
- Aggregated volume
- Price
Not applicable - single transaction
e)
Date of the transaction
22 November 2023
f)
Place of the transaction
LON
AstraZeneca
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical
company that focuses on the discovery, development, and commercialisation of
prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals,
including Cardiovascular, Renal & Metabolism, and Respiratory &
Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries
and its innovative medicines are used by millions of patients worldwide.
Please visit astrazeneca.com (http://www.astrazeneca.com/) and follow the
Company on Twitter @AstraZeneca (http://www.twitter.com/AstraZeneca) .
Contacts
For details on how to contact the Investor Relations Team, please click here
(https://www.astrazeneca.com/investor-relations.html#Contacts) . For Media
contacts, click here (https://www.astrazeneca.com/media-centre/contacts.html)
.
Adrian Kemp
Company Secretary
AstraZeneca PLC
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END DSHUORSROSUAUAA